PPARG and adrenal cortex neoplasm: Since the first clinical application of PPARG agonists, thiazolidinediones (TZD) in 1997, there have been various studies exploiting the activation of PPARG pathway in various pathologies, including CD, regulation of steroidogenesis and adrenocortical tumors with varying results (34).